Anthony Amato, MD
Neurology · Boston, MANPI 1124009881
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $14,569 of the $19,092 with a category attached, or 76.3%. It is spread thinly across 15 manufacturers, the largest accounting for just 21.6%. 2025 is the largest year on record at $8,643, more than ten times the $122 reported in 2019.
Across 31 payments — averaging $615.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$4K
- Novartis Pharma AG$4K
- Amgen$3K
- Sanofi US Services Inc.$3K
- UCB, Inc.$1K
- Janssen Research & Development, LLC$1K
- plus $3K from 9 others
Across 59 payments — averaging $41,352 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Leadiant Biosciences, Inc.$2.3M
- UCB SA$46K
- Janssen Research & Development, LLC$30K
- AstraZeneca$24K
- Argenx US, Inc.$11K
- E.r. Squibb & Sons, L.L.C.$10K
- plus $610 from 1 others
What the payments were for
- Consulting fees$14,56976%
- Speaking & faculty fees$3,00016%
- Food & beverage$1,5238%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 1 | $4,125 |
| Novartis Pharma AG | 1 | $3,713 |
| Amgen | 1 | $3,000 |
| Sanofi US Services Inc. | 2 | $2,926 |
| UCB, Inc. | 14 | $1,292 |
| Janssen Research & Development, LLC | 1 | $1,150 |
| AstraZeneca | 2 | $841 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $525 |
| EMD Serono, Inc. | 1 | $450 |
| Astellas Pharma Inc | 1 | $440 |
| EMD Serono Research & Development Institute, Inc. | 1 | $400 |
| CSL Behring | 1 | $122 |
| Acadia Pharmaceuticals Inc | 2 | $44 |
| Argenx US, Inc. | 1 | $36 |
| Grifols Shared Services North America, Inc. | 1 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,092 in reported general payments places this provider in the 85th percentile of 761 neurology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FirdapseAmifampridine Phosphate | 14 | $798,126 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 39 | $609,439 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 39 | $372,805 |
| Mycophenolate Mofetil | 38 | $6,619 |
| Pyridostigmine Bromide | 40 | $2,111 |
| Prednisone | 66 | $327 |
| MethotrexateMethotrexate Sodium | 18 | $314 |
| Gabapentin | 14 | $265 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHizentra | $122 | $609,43939 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 761 neurology providers in Massachusetts.
Other neurology in Boston
- Christopher WrightBoston$2.5M
- Thomas ScammellBoston$617K
- Alfred SandrockBoston$490K
- Pushpa NarayanaswamiBoston$420K
- Roy FreemanBoston$390K
- Michael LevyBoston$387K
- Leeann BurtonBoston$325K
- Ilena GeorgeBoston$316K
- Andrew BudsonBoston$304K
- Denis BalabanBoston$297K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.